A practical, gold-standard clinical test for oncologists to quickly screen for LEMS is to ask a patient to stand from a chair without using their arms. An inability to do so is a strong, immediate indicator of proximal leg weakness—a hallmark of LEMS—and should trigger a more comprehensive workup.

Relying solely on the VGCC antibody test for LEMS is insufficient. Experts advise ordering a broader panel upfront, including SOX1 and a standard paraneoplastic reflex panel. This approach saves time and provides a comprehensive picture immediately, preventing the need to chase additional tests weeks later.

A diagnosis of myelofibrosis without a JAK2, CALR, or MPL mutation should be treated as a red flag, not a final diagnosis. It warrants a deeper investigation for alternative causes, such as MDS/MPN overlap syndromes or secondary fibrosis from other conditions like autoimmune disease or hairy cell leukemia.

A negative liquid biopsy (ctDNA) result for HER2 amplification does not prove a patient is HER2-negative. The test's sensitivity is limited by tumor fraction in the blood. While a positive ctDNA result is highly specific and trustworthy, a negative result is simply 'not detected' and requires a tissue biopsy to definitively determine HER2 status for treatment decisions.

To effectively diagnose LEMS, healthcare systems must implement systemic changes rather than relying on individual clinician awareness. This includes using tumor boards for unexplained weakness, treating VGCC results as critical lab values requiring a direct handoff, and building bundled order sets for testing and referrals to create a reliable diagnostic pathway.

Experts express concern that the paraneoplastic syndrome LEMS is frequently missed in SCLC patients. Its primary symptom, proximal muscle weakness, is often attributed to the cancer itself or treatment side effects, leading clinicians to overlook the specific diagnostic test for this distinct and potentially treatable condition.

A standard nerve conduction study will often miss LEMS because it doesn't include the necessary protocols. To ensure an accurate diagnosis, the referral must explicitly state to 'evaluate for LEMS' or 'presynaptic neuromuscular junction dysfunction.' This instruction triggers the required rapid stimulation and exercise components essential for detection.

Oncologists should be highly suspicious of LEMS when a patient's functional decline is disproportionate to their cancer's response to treatment. If imaging shows tumors are shrinking but the patient is getting weaker, this mismatch is a critical signal that a distinct paraneoplastic process is at play and warrants immediate investigation.

Symptomatic treatment for LEMS, such as with amifampridine (Firdapse), is not just for quality of life. Its primary strategic goal is to optimize a patient's performance status, making them strong enough to tolerate more aggressive and effective cancer-directed treatments like chemotherapy and immunotherapy, which can improve overall cancer outcomes.